Empfehlungen zu Blutuntersuchungen und klinischer Überwachung zur FrÜherkennung des Valproat-assoziierten Leberversagens
| Autor: | St. A. König, H. E. Boenigk, H. Schneble, T. Mayer, P. A. Despland, F. Vassella, D. Schmidt, P. Wolf, H. Nau, P. Genton, H. Siemes, H. Stefan, A. Bergmann, W. Löscher, Günter Krämer, Christian E. Elger |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Valproic Acid Pediatrics medicine.diagnostic_test business.industry Blood Screening Liver failure General Medicine Psychiatry and Mental health Neurology medicine Neurology (clinical) Neurosurgery Liver function tests Adverse effect business Complication Blood coagulation test medicine.drug |
| Zdroj: | Der Nervenarzt. 69:835-840 |
| ISSN: | 1433-0407 0028-2804 |
| DOI: | 10.1007/s001150050351 |
| Popis: | Valproate is a frequently used antiepileptic drug. It is associated with rare but serious adverse effects like liver failure. The first symptom is impairment of the patient's well being. Isolated changes of standard laboratory liver parameters are not reliable early indicators. Thus, according to the knowledge of today, prophylactic blood screening cannot predict complications. On the contrary, clinical symptoms are the most relevant indicators of impending complications, eventually supported by laboratory findings. An abrupt withdrawal of valproate and administering carnitin in parallel can interrupt the otherwise fatal course of the complication and induce a subsequent recovery. At a Consensus Conference the current knowledge about early detection and therapy of the valproate-induced serious hepatotoxicity was discussed. The results regarding recommended laboratory screening, as well as diagnostic and therapeutic strategies are reported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink